FDA Says Merck's Chronic Cough Treatment Didn't Show Substantial Evidence of Effectiveness
20 Dezembro 2023 - 7:27PM
Dow Jones News
By Ben Glickman
Merck's candidate to treat chronic cough didn't show substantial
evidence of effectiveness, according to the Food and Drug
Administration.
The Rahway, N.J.-based pharmaceutical company said Wednesday it
received a complete response letter from the FDA regarding its new
drug application for gefapixant, a potential treatment for
refractory chronic cough or unexplained chronic cough in
adults.
The company said the letter wasn't related to the safety of the
treatment, and it was reviewing FDA feedback to determine the next
steps.
RCC is a persistent cough that continues despite treatment of
underlying conditions, while UCC is a persistent cough without an
identified underlying cause.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 20, 2023 17:12 ET (22:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
